|
🦁
|
Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators
12 auth.
S. Canturk,
I. Qaddoumi,
V. Khetan,
Zhigui Ma,
A. Furmanchuk,
C. Antoneli,
...
I. Sultan,
R. Kebudi,
T. Sharma,
C. Rodríguez-Galindo,
D. Abramson,
G. Chantada
|
7 |
2010 |
7
🦁
|
|
🐜
|
Strategies to manage retinoblastoma in developing countries
11 auth.
G. Chantada,
I. Qaddoumi,
S. Canturk,
V. Khetan,
Zhigui Ma,
K. Kimani,
...
Barış Yeniad,
I. Sultan,
R. Sitorus,
N. Taçyıldız,
D. Abramson
|
7 |
2011 |
7
🐜
|
|
🐜
|
Familial retinoblastoma in developing countries
12 auth.
G. Chantada,
I. Dunkel,
I. Qaddoumi,
C. B. Antoneli,
A. Totah,
S. Canturk,
...
I. Nawaiseh,
A. Fandiño,
I. Pífano,
G. Peksayar,
K. Ribeiro,
D. Abramson
|
5 |
2009 |
5
🐜
|
|
🐬
|
Toxic keratopathy due to abuse of topical anesthetic drugs
Barış Yeniad,
S. Canturk,
Fatma Esin Ozdemir,
Nilufer Alparslan,
K. Akarçay
|
4 |
2010 |
4
🐬
|
|
🐬
|
Bilateral acquired Brown syndrome in systemic scleroderma.
A. Gezer,
S. Tuncer,
S. Canturk,
E. Kasapoğlu,
A. Çimen,
M. Inanç
|
2 |
2005 |
2
🐬
|
|
🐜
|
Chemoreduction and local ophthalmic therapies in intraocular retinoblastoma
8 auth.
R. Kebudi,
I. Ayan,
S. Canturk,
G. Peksayar,
Omer Orgun,
S. Tuncer,
...
Ermin Darendereliler,
F. Agaoglu
|
0 |
2007 |
0
🐜
|
|
🐬
|
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
H. Hacisahinogullari,
S. Canturk,
S. Doğanşen,
S. Yarman
|
0 |
2022 |
0
🐬
|
|
🐬
|
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
H. Hacisahinogullari,
S. Canturk,
S. Doğanşen,
S. Yarman
|
0 |
2022 |
0
🐬
|
